How Risky Are These Stocks? Vitesse Semiconductor (VTSS), Francesca’s Holdings Corp (FRAN) and BioCryst Pharmaceuticals Inc (BCRX)

Posted by admin March 26, 2015 0 Comment 459 views

New York, NY – GDP INSIDER  –  03/26/2015.

This article discusses three companies: Vitesse Semiconductor (NASDAQ:VTSS), Francesca’s Holdings Corp (NASDAQ:FRAN) and BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

Vitesse Semiconductor (NASDAQ:VTSS) fell back slightly yesterday with the stock declining 0.38% or $0.02 to close at $5.29 on very active trading of 3.176 million shares. The developer and manufacturer of integrated circuits has been riding high for the last week, after Microsemi Corporation (NASDAQ:MSCC) agreed to buy out the company for $5.28 per share, equivalent to $389 million dollars in cash. Vitesse still has until April to find another buyer with a higher offer which could boost the stock price even higher, making the stock a definite hold until this deal is closed.

Could Vitesse Be Worth Even More? Take A Look At The Fundamentals With Free VTSS Analysis.  

Francesca’s Holdings Corp (NASDAQ:FRAN) dropped 5.40% or $0.91 yesterday to close at $15.93 on heavy trading of 2.498 million shares, compared to its three month average trading volume of 0.590 million. The accessories and apparel retail chain started to decline after it announced a much lower than expected first quarter and full year forecast. For the first quarter Francesca’s Holdings Corp now expects $0.15 to $0.18 earnings per share compared to the market consensus estimate of $0.21 and full year $0.81 to $0.90 as opposed to the market forecast of $0.94, making it a hold for now.

Do The Technical Indicators Point To A Quick Recovery? Take A Closer Look With Free FRAN Analysis.

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) continued its recent decline with the stock dropping another 7.74% or $0.68 to close at $8.10 with more than 1.627 million shares changing hands, compared to its three month average trading volume of 0.840 million. The designer and optimizer of therapeutic enzymes has been losing value since the beginning of the year and has now lost 33.39% of its value YTD. With quarterly revenue decline of 48.50% year on year and diluted EPS of -$0.68, even with its current RSI of 25.28 it is better to sell than to hold at this time.

Can BioCryst Pharmaceuticals Inc Bounce Back? Click Here For Free BCRX Analysis.

About UltimateStockAlerts provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

Write Your Comment